^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Source:
Title:

miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: A retrospective analysis of the PETACC-8 trial

Published date:
10/01/2018
Excerpt:
The PETACC-8 phase III trial assessed the efficacy of cetux addition to FOLFOX compared to FOLFOX only in pts with resected stage III colon cancer (CC)....Pts with low miR-31-5p levels (n = 233/477, 49%) benefited from cetux on DFS (HR = 0.46 [0.25; 0.84] p = 0.01) and OS (HR = 0.50 [0.25; 0.99], p = 0.047) whereas high expressers did not (DFS: HR = 0.87 [0.56; 1.34] ; OS: HR = 1.01 [0.61; 1.67]).
DOI:
10.1093/annonc/mdy281.068
Trial ID: